

## (2S,3R)-Voruciclib hydrochloride

### Chemical Properties


CAS No. :

Formula: C<sub>22</sub>H<sub>20</sub>Cl<sub>2</sub>F<sub>3</sub>NO<sub>5</sub>

Molecular Weight: 506.3

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



### Biological Description

|               |                                                                                                                                                                          |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description   | (2S,3R)-Voruciclib hydrochloride is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor.                                                          |
| Targets(IC50) | Others                                                                                                                                                                   |
| In vitro      | (2S,3R)-Voruciclib (Compound B, formula I) is used in combination with a compound capable of inhibiting EGFR kinase activity and Gemcitabine to treat pancreatic cancer. |

### Solubility Information

|            |                                                                                                    |
|------------|----------------------------------------------------------------------------------------------------|
| Solubility | DMSO: 250 mg/mL (493.78 mM),<br>( $< 1$ mg/ml refers to the product slightly soluble or insoluble) |
|------------|----------------------------------------------------------------------------------------------------|

### Preparing Stock Solutions

|       | 1mg       | 5mg       | 10mg       |
|-------|-----------|-----------|------------|
| 1 mM  | 1.9751 mL | 9.8756 mL | 19.7511 mL |
| 5 mM  | 0.395 mL  | 1.9751 mL | 3.9502 mL  |
| 10 mM | 0.1975 mL | 0.9876 mL | 1.9751 mL  |
| 50 mM | 0.0395 mL | 0.1975 mL | 0.395 mL   |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

### Reference

Veena Agarwal, et al. A synergistic pharmaceutical combination for the treatment of pancreatic cancer. WO2012123889A1.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286    E\_mail:info@targetmol.com    Address:36 Washington Street,Wellesley Hills,MA 02481